Therapeutic Effects of Holmium-166 Chitosan Complex in Rat Brain Tumor Model by 諛뺤슜援� et al.
Yonsei Medical Journal
Vol. 46, No. 1, pp. 51 - 60, 2005
Yonsei Med J Vol. 46, No. 1, 2005
This study examined the effectiveness of Holmium-166
(Ho-166) chitosan complex therapy for a malignant glioma.
Cultured C6 glioma cells (100,000 in 5 lμ ) were injected into
the caudate/putamen of 200 - 250 gram Wistar rats. Five days
later, a Ho-166 chitosan complex was injected into the same
site of the glioma injection. Four injection doses were adminis-
tered: the control group received PBS 10 l, group 1 receivedμ
an injection of 100 Ci (10 l), group 2 received an injectionμ μ
of 50 Ci (5 l), and group 3 received an injection of 10 Ciμ μ μ
(1μl). The average tumor volume for each group was 1.385
mm3 for the control group, 0.036 mm3 for group 1, 0.104 mm3
for group 2, and 0.111 mm3 for group 3. Compared with the
control group, the size of the tumors in groups 1, 2 and 3 was
reduced by an average of 97.4%, 92.5% and 91.9%, respec-
tively. The Kaplan-Meier survival curve of group 2 was the
longest, followed by groups 3, group 1 and the control. The
mean survival was 22.8, 59, 60, and 44.6 days for the control
group and groups 3, 2 and 1, respectively. H-E staining re-
vealed that group 2 yielded the best results in the destruction
of the malignant glioma. TUNEL staining and immunohisto-
chemical studies indicated apoptotic features. The Ho-166
chitosan complex proved to be effective in destroying the
malignant glioma.
Key Words: Holmium-166 chitosan complex, malignant glioma,
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INTRODUCTION
A malignant glioma that occurs in the brain
tends to invade the surrounding tissue. Conse-
quently, this tumor cannot be removed completely
by a simple resection using a craniotomy. More-
over, it does not respond well to chemotherapy or
radiotherapy, which means that such treatment
methods serve merely as a supplementary role in
the prolongation of life. Despite the advances in
modern medicine, the growth of a tumor cannot
be effectively repressed or controlled with sur-
gery, chemotherapy, radiotherapy or recent im-
munotherapy and gene therapy especially for
malignant gliomas.1-3
Nevertheless, radiotherapy is the treatment that
offers temporary relief. External beam radiation is
most widely used, and radiosurgery using a linear
accelerator or a Gamma knife has recently been
tried. Theoretically, the use of stereotactic tech-
niques may play a role in escalating the radiation
dose safely. However, such a high dose is asso-
ciated with a higher risk of unacceptable normal
tissue toxicity.
In order to reduce the side effects of radio-
therapy and to enhance the treatment effects of
malignant brain tumors, it is necessary to localize
the radiation on the tumor area precisely, for
which a treatment method using a radionuclide
with weak penetration power within the tissues
would be useful i.e. a -emitting radionuclide.β
When using radiation with a weak penetration
power, its isotopes should be inserted into the
tumor tissues. This method is known as brachy-
therapy using isotopes such as irridum-192, palla-
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dium-103, and iodine-125.4-6 However, brachy-
therapy for brain tumors requires complicated
surgical procedures, which involve the insertion
and fixation of the radioactive isotopes for a cer-
tain period of time and then removing them. This
procedure has a high chance of recurring compli-
cations such as infection, hemorrhage, and tumor
metastasis of7,8 In order to overcome these limita-
tions, radiopharmaceuticals that are injected as
liquids, diffuse into the tissues, and become gelati-
nized after a certain period of time in order to be
retained in the tissue would be ideal. Ho-166
emits rays with a high energy and a short half-β
life of 26.83. It decays to stable daughter products
and has a higher energy corresponding to Y-90 by
emitting 94% rays [average 0.61 MeV, maxiβ -
mum 1.766 MeV (48%), 1.855 MeV (51%)] and 6%
γ rays [0.081 MeV (6.24%), 1.379 MeV (0.93%)].
Because Ho-166 emits a small proportion of γ
rays, it can generate an image on the gamma
camera. The penetration range of Ho-166 into the
soft tissues is 1.23 mm on average, with a
maximum of 8.6 mm. When it is injected into the
tumor, 90% of the energy is deposited within the
range of 2.1 mm, and the remaining 10% is de-
posited within the range of 2.1 - 8.6 mm, sug-
gesting that it is intensively irradiated on the
tumor only, whilst preserving the surrounding
normal tissues. Therefore, Ho-166 has been suc-
cessfully used in animal experiments using inter-
nal radiotherapy.9-11 In addition, chitosan, as a
chelating agent, has been attracting increasing
attention as a biomaterial and as a pharmaceutical
excipient for drug delivery owing to its favorable
biological properties. Chitosan is obtained by the
N-deacetylation from chitin, which is the second
most common natural polymer. The N-deacety-
lation of chitin leads to a cationic polymer, which
has a pH-dependent solubility in water. It exists
in liquid form when the acidity is 4.0 or lower,
and after it is injected into the body and meets the
neutral body fluid, it becomes gelatinized as the
pH increases to 6.5. Because of these character-
istics, chitosan has the potential to be retained at
the injected site for a long period of time.
12-14
Therefore, Ho-166-chitosan complex can theoreti-
cally prevent the side effects caused by the radio-
action that can occur by using these radioisotopes
internally, by not remaining in the area of the
injection and by extending to other internal or-
gans. Furthermore, it can avoid the limitation of
having to remove the radioisotopes that have been
inserted.14
The aim of this study was to identify the effects
of a Ho-166-chitosan complex on the destruction
of a malignant brain tumor and the repression of
its growth in rats as a preliminary step prior to
attempting clinical trials on patients with a malig-
nant brain tumor. Primarily, the reactions of the
brain tissues in the rats whose cell strain of C6
glioma had been xenografted were compared with
the brain tissues of normal rats. At the same time,
the survival rate of the rat tumor model was
determined.15,16 Finally, the progression processes
of apoptosis and necrosis in the residual tumor
cells were examined using immunohistochemical
stains such as transferase-mediated deoxyuridine
triphosphate nick end labeling (TUNEL) stains,
and Bcl-2 and Bax stains.
MATERIALS AND METHODS
Incubation of tumor cells
The cell strain of the C6 glioma was incubated
in Dulbecco's modified Eagle's medium (DMED;
Pharmacia, Peapack, NJ, USA) containing 10% fe-
tal bovine serum (HyClone; Sigma, St. Louis, MO,
USA). All the incubated substances included 2 mM
L-glutamine and gentamycin per 50 g/ml. Allμ
the cells were incubated at 37 in 5% CO2/ 95%
air. The adhered cells were trypsinized in DMEM
before being transplanted in the albino rats.
Tumor cell transplantation and injection of Ho-
166 chitosan complex
The rats were anesthetized with ketamine (75
mg/kg), acepromazine (0.75 mg/kg), and rompun
(4 mg/kg), and the tumor cells were injected into
the cranium using a Hamilton syringe (Fischer
Scientific, Tustin, CA, USA) with 30-gauge oblique
needles. The target coordinates were 2.5 mm left
from the bregma and 5.5 mm deep from the dura
mater. The total number of C6 glioma cells to be
transplanted was 100,000 in 5 l, and to preventμ
any leakage the injection needle was left in place
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for 4 minutes after the 5-minute injection, which
was then slowly removed over a 1 minute period.
Five days after the tumor cell transplantation, 10
l of 100μ Ci, 5 l of 50μ μ Ci, and 1μ l of 10μ Ci ofμ
Ho-166 chitosan complex, and 5 l of normalμ
saline, in groups 1, 2, 3, and the control, respec-
tively, were injected into the same area in the
same manner as in the tumor cell transplantation
for the four different groups, each of ten 200 - 250
gram Wistar rats. In order to calculate the survival
rate, a follow-up observation was carried out until
death on five of the ten rats in each group without
obtaining tissue specimens.
Tissue preparations
Of the other five rats, four were anesthetized
with ether and sacrificed 5 days after injecting the
Ho-166 chitosan complex injection, and their chests
were excised. The right atriums were incised and
a cannula was inserted into the left ventricle, which
was refluxed in 120 mM NaCl/2.7 mM KCL con-
taining a 10 mM phosphate buffer of pH 7.4 and
3.7% paraformaldehyde. The brain was immersed
in the same fixing fluid for 30 minutes, and frozen
with dry ice after a low temperature treatment in
30% sucrose phosphate-buffered saline (PBS). The
tissue sections were sliced at a 12μm thickness,
and mounted on slides coated with chrome alum/
gelatin.
Measuring the effects of the transplanted cells
and Ho-166 chitosan complex injection
The cross-sectional area of the tumor region and
the number of transplanted cells per tumor sec-
tion were measured by image analysis using a
Microcomputer imaging device. The estimated
value for the entire tumor volume was induced
from the tumor area with the largest cross-section.
The degree of Ho-166 chitosan complex penetra-
tion into the tumor area was examined using his-
tological tests, and the tissue was stained with
Hematoxylin-Eosin (H&E) staining method and
observed microscopically.
TUNEL staining
The brain tissue of the rat model with a brain
tumor, which had been damaged by the Ho-166
chitosan complex embedded in the paraffin was
sliced at a 4 mm thickness, mounted on a tissue
slide, dried at room temperature, and the paraffin
was removed using xylene. After proteinase K
(DAKO Corp., Carpinteria, CA, USA) was dropped
onto the tissue and reacted at room temperature,
the target area that had been covered during
fixation became exposed via proteolytic digestion.
The tissue slide was soaked in 3% hydrogen per-
oxide in PBS for 5 minutes at room temperature
in order to quench the endogenous peroxidase
reaction, and washed in the normal saline solu-
tion. The other rat brain tissues were stained
using a kit (ApopTag Peroxidase kit, Intergen Co.,
Purchase, NY, USA). An equilibration buffer was
dropped onto the slide until the tissue was cov-
ered, reacted at room temperature, and lightly
swept away, while the working strength TdT en-
zyme, which was made by combining the reaction
buffer and TdT enzyme at a ratio of 7 : 3 was ad-
ded and incubated in a 37 humidified chamber
for 1 hour. After leaving the 1 hour-incubated
tissue slide in the stop/wash buffer, the slide was
incubated for 10 minutes at room temperature
whilst being slightly shaken. Subsequently, the
slides were washed with a normal saline solution,
while an anti-digoxigenin peroxidase conjugate
was applied, and incubated for 30 minutes in a
humidified chamber at room temperature. After
washing the slide with a normal saline solution,
the color was developed with a DAB solution at
room temperature. Within the damaged tissues,
the number of stained cells was measured from
the area where the TUNEL staining was most
frequently detected by optical microscopy at a 200
x magnification.
Immunohistochemical staining
Immunohistochemical staining was carried out
using the Bcl-2 antibody (Polyclonal rabbit anti-
rat/mouse Bcl-2 antibody, Pharmingen Co., San
Diego, CA, USA), which is known to repress
apoptosis, and the Bax antibody (Polyclonal rabbit
anti-mouse/rat Bax antibody, PharMingen Co.,
San Diego, CA, USA), which facilitates apoptosis
in the Bcl-2 family on the cerebral tissue fixed in
paraffin. The color was developed after reacting it
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with a biotin-combined second antibody.
The primary antibody (anti-Bcl-2 Ab, anti-Bax
Ab) was applied to the tissue, which was incu-
bated at 4 for 30 minutes and at room tempera-
ture overnight. After washing the tissue with PBS,
it was incubated for 10 minutes after applying the
biotinylated anti-rabbit/anti-mouse immunoglo-
bulin provided in the kit (DAKO LSAB kit, DAKO
Corp., Carpinteria, CA, USA). After rinsing with
PBS, it was incubated for 10 minutes after apply-
ing streptavidin peroxidase. After further washing
with PBS, the color was developed using DAB
(3,3-diaminobenzidine, DAKO Corp., Carpinteria,
CA, USA).
The tissues of the brain tumor were observed
microscopically at a 200 × magnification, from the
area where the Bcl-2 or Bax staining was most
frequently detected.
RESULTS
Survival rate and changes in the tumor size
After the injection of the Ho-166 chitosan com-
plex on the fifth day after the transplantation of
the cultured tumor cells, 10 l of 100μ Ci, 5μ l ofμ
50 Ci, and 1μ l of 10μ Ci of the Ho-166 chitosanμ
complex, and 5 l of PBS were injected into eachμ
group. After 5 days, 4 rats from each group were
sacrificed to obtain the brain tissue specimens. It
was verified that the tumor transplantation had
been done successfully in all tissues (Fig. 1). The
size of the tumor (mm
3
) was calculated using the
formula of 4/3p width (a, m) length (bμ , mμ ) and
depth (c, m).μ
The percentage reduction of the tumor volume
relative to that in the control group was 97.4%,
92.5%, and 91.9% in groups 1, 2 and 3, respec-
tively showing a decreasing rate (Table 1, Fig. 2).
Furthermore, by injecting each dose into the
normal brain and grossly observing it, group 1
showed cavitation involving extensive destruction
around the area of the injection. Although groups
2 and 3 showed destruction of the brain tumor
tissues around the area of the injection, there was
no observation of cavitation as extensive as ob-
served in group 1.
In order to calculate the survival rate, 5 experi-
mental rats were kept alive until their natural
death without obtaining tissue specimens. The
Kaplan-Meier survival curve was the longest in
group 2, which was followed by groups 3 and 1,
and finally the control group. The median sur-
vival times were calculated for each group. The
median survival time was 22 days in the control
group, 60 days in group 3, 60 days in group 2, and
36.5 days in group 1. The difference in the sur-
vival rate of each group was statistically signi-
ficant (p < 0.001, Fig. 3).
Table 1. Tumor Volume for Each Group
Group Volume (mm3) Percentage (%)
Control (n=4) 1.385 ± 0.74 100.0
Group 1 (n=4) 0.036 ± 0.029 2.6
Group 2 (n=4) 0.104 ± 0.066 7.5
Group 3 (n=4) 0.111 ± 0.032 8.0
Fig. 1. Gross images for each group. In the control group,
a successful tumor implant in the left putamen can be
observed. In group 1, cavitation (arrows) can be observed
in spots where the Ho-166 chitosan complex was over-
administered. In groups 2 and 3, the implanted tumors are
substantially reduced in size due to destruction by Ho-166
chitosan complex.
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Comparison of the histopathological findings
Findings on H-E staining
On the fifth day after injecting the Ho-166
chitosan complex, 4 rats in each group were sacri-
ficed in order to obtain tissue specimens of the
malignant cerebral glioma.
H-E staining of the cerebral glioma located in
the putamen showed a malignant cerebral glioma
with abundant cytoplasm and nuclei. Compared
with the control group, group 1 showed cavitation
where almost all the cells were destroyed and a
coagulation necrosis of tumor cells was observed.
In contrast, group 2 did not show any cavitation
at the center of injection but there was a coagula-
tion necrosis of cells with hypochromasia and no
observation of nuclei. The tumor cells that had
become necrotic were arranged in the shape of a
belt, and living tumor cells were observed in the
surrounding area. In group 3, the range of coagu-
lation necrosis was not as wide as observed in
group 2, and more live tumor cells were observed
than in group 2 (Fig. 4).
Results of TUNEL staining
TUNEL staining indicated that all three of the
experimental groups that had been injected with
the Ho-166 chitosan complex showed a positive
finding where the nucleus was positively stained,
and the frequency of benign cells was higher than
the capacity of the Ho-166 chitosan complex. This
means that the average benign findings observed
Fig. 2. Comparison of the tumor volume for each group.
The average tumor volume for the control group was
1.385 mm3. For group 1, it was 0.036 mm3, for group 2, it
was 0.104 mm
3
, and for group 3 it was 0.111 mm
3
. The
ratio of the tumor volume against the control volume was
97.4% for group 1, 92.5% for group 2, and 91.1% for
group 3, showing a gradual reduction.
Fig. 3. Survival curve for each group. Curves for groups
2 and 3 extended further than the control and group 1,
and this extension was statistically significant (p < 0.001).
Fig. 4. H&E stain images. Under 100 × and 400 × magnification, malignant cerebral tumors with abundant nucleus and
cytoplasm could be observed in the control group. In group 3, some tumor cells destroyed by Ho-166 chitosan complex
could be observed, but the areas with active tumor cells were larger than in the other groups. In group 2, necrosis of the
tumor cells were observed more extensively. In group 1, cavities (almost all cells completely destroyed with no structure)
could be observed around the centers of administration (marked with arrow). Destruction spread even into normal tissues,
and tumor cells showed the appearance of coagulation necrosis.
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by optical microscopy at 200×magnification were
19.6%, 30.4%, and 36.7% in groups 1, 2 and 3,
respectively. There was a positive reaction ob-
served in the area that appeared to be a radione-
crosis in the normal cells around the tumor cells
in group 3 (Table 2, Fig. 5, 6).
Findings of the immunohistochemical staining
For the Bax antibody, there was extensive cyto-
plasm staining observed around the area where
the tumor had been destroyed in group 1 (Fig. 7).
Although there was a similar finding in group 2,
group 3 showed almost no staining. For Bcl-2,
none of the groups showed any staining (data not
shown).
DISCUSSION
More than half of the gliomas, which make up
40 - 50% of all primary brain tumors, were malig-
nant. Although they do not metastasize to other
organs, they infiltrate into the surrounding nor-
mal tissues around the area of occurrence. In ad-
dition, most of them relapse despite active treat-
ments such as surgery, radiotherapy, and chemo-
therapy due to their very rapid speed of growth
rate. The prognosis is very poor with an average
survival time of 1 year or less.
3,17
Local infiltration of the tumor is a special fea-
ture of a malignant glioma that makes a complete
recovery impossible. The infiltration is known to
extend up to 2 - 3 cm from the area of the contrast
enhancement on diagnostic imaging.
18
The primary treatment for a brain tumor is the
surgery. The aim of surgery is to maximize the ef-
fects of the supplementary treatment by removing
as much of the tumor as possible without causing
neurological impairment and to assist in the his-
tological diagnosis. Although diagnostic imaging
Fig. 5. TUNEL stain images. In all experimental groups with the Ho-166 chitosan complex administration, there were
positive results with the nucleus being stained (arrowed). In group 3, positive reactions were observed even in the normal
cells around a tumor cell where it appeared to be going through radionecrosis.
Fig. 6. Comparison of TUNEL-stain-positive rats. The
average positive rates were 19.6% for group 3, 30.4% for
group 2, 36.7% for group 1.
Table 2. Percentages of TUNEL Positive Cells for Each
Group
Group Positive cells by TUNEL staining (%)
1 36.7 ± 17.1
2 30.4 ± 10.7
3 19.6 ± 16.1
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tools, surgical tools, and surgical techniques have
advanced by leaps and bounds, a complete reco-
very is impossible with surgery alone, and sup-
plementary treatments such as radiotherapy, che-
motherapy, and immunotherapy, in addition to
gene therapy, which is in the early stage of re-
search, are being performed. BCNU, ACNU, and
PCV (procarbazine, lomustine, and vincristine)
have been used for chemotherapy, but their effects
are weaker than those for the tumors in other in-
ternal organs. This is because of the heterogeneity,
the blood-brain barrier, the blood-tumor barrier,
and the low blood stream volume of the tumor
cells. In order to overcome the insufficient deli-
very of the drug as a result of the blood-brain
barrier and the blood-tumor barrier, interstitial
chemotherapies using an injection pump, catheter,
and polymer have been introduced. 5-FU, metho-
trexate, bleomycin, cisplatin, and ACNU have
been used, but without any improvement in the
treatment effects.19
Immunotherapy and gene therapy for a cerebral
glioma have been developed as a result of the
poor specificity and selectivity of the previous
treatment methods. The side effects are severe
with high IL-2 or TNF- doses. Interferonα - isβ
being clinically used but its definite therapeutic
effects have not been proven. Active studies on
gene therapy are being carried out along with the
recent development of molecular and cell bio-
logy.1,2
Radiotherapy has been proven to be the most
effective supplementary treatment, and the sur-
vival rate of cerebral glioma patients has doubled
over the last 10 years.2,3 However, such radio-
therapeutic methods often cause radionecrosis as
a result of irradiation on the surrounding normal
tissues, resulting in various side effects such as a
cerebral edema. Such side effects can aggravate
the neurological symptoms in the patients, inter-
rupt the patients' normal living for the rest of
their lives, and can even lead to death if severe
enough.20-23
Brachytherapy, which is performed to enhance
the treatment effects and reduce the side effects
associated with radiotherapy, is a treatment
method that uses a toxic dosage of radiation to the
specific tumor while minimizing the irradiation
on the surrounding normal tissues. However,
brachytherapy for cerebral tumors requires com-
plicated surgical procedures that involve the
insertion and fixation of the radioactive isotopes
for a certain period of time and then removal of
them. Accordingly, there is a high probability of
complications such as infection, hemorrhage, and
metastasis. In order to complement such limita-
tions, isotopes that are injected as liquids, pene-
trate the tissues, and finally become gelatinized
after a certain period of time would be ideal.5,6
Lee et al. reported the treatment effect of the
Ho-166 chitosan complex by injecting it directly
into the hepatoma (SK-HEP1) through a subcuta-
neous transplantation into the nude mouse, re-
sulting in the radionecrosis of the hepatoma with
almost no side effects on the other tissues or in-
ternal organs.24 The therapeutic effects of the Ho-
166 chitosan complex have been proven using
animal experiments and clinical studies in various
Fig. 7. Bax stain results. In group 1, extensive staining of the cytoplasm could be observed around the tumor destruction
as the center. In group 2, similar observations were made. However, in group 3, there appeared to be barely any staining.
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types of skin cancers or Bowen's disease. In addi-
tion, it has also shown good therapeutic effects for
squamous cell carcinoma, basal cell carcinoma,
and Bowen's disease in clinical studies using a
specially designed, Ho-166 chitosan complex-at-
tached, skin patch.10,11 Good results for knee bur-
sitis have also been shown in rheumatoid arthritis
patients.25 Suzuki et al have reported the results
of the biodistribution and kinetics of intrahe-
patically administered Ho-166-chitosan complex
and 166Ho alone in rats. They found that most of
the administered radioactivity was exclusively
retained at the administration site for over 72 hr.
On the other hand, the intrahepatic administration
of 166Ho alone showed a higher radioactive con-
centration in the blood from the early period, and
evidence that it had spread to many tissues
indicated that the effective biological half-life at
the administration site was much longer than that
at the other tissues.26
In order to clinically use such isotopes for a ma-
lignant cerebral glioma, the presence or absence of
the tumor necrosis by the Ho-166 chitosan com-
plex, its range along with its appropriate injection
volume should all be calculated. Lee et al. directly
injected a Ho-166 chitosan complex into a hepa-
toma (SK-HEP1) through subcutaneous transplan-
tation into nude mice. Despite the fact that the
entire volume injected was small at 0.025 ml, 3.7
mCi was reported to achieve complete necrosis of
a 1 cm diameter hepatoma, and only 10.94 mCi
was needed for a 2 cm diameter tumor.25 It was
separately reported that when 1 mCi was injected
into a skin melanoma transplanted to a white rat,
with an average tumor size of 1 cm, there was the
possibility for complete elimination.12 In this study,
the average tumor volume was 1.385 mm3 for the
control group, 0.036 mm3 for the 100 Ci injectionμ
group, 0.104 mm3 for the 50 Ci injection group,μ
and 0.111 mm
3
for the 10 Ci-injection group. Asμ
noted previously, there was some variation in the
tumor volume (Table 1), but this was not statisti-
cally significant. The percentage reduction for the
tumor volume relative to that in the control group
was 97.4%, 92.5%, and 91.9% in groups 1, 2 and
3, respectively, all showing a tumor-volume de-
crease rate of over 90%. However, group 1 showed
extensive cavitation that involved the normal
tissues resulting in a marked decrease in the sur-
vival rate compared with that of the other groups.
This was considered to be not only due to the ex-
cessive radiation dose, but also because of the ex-
cessive injection dose (10 μl) and the fact that the
injection dose was not quantified in each group.
The survival rates in groups 2 and 3 were signifi-
cantly higher than in the control group (p < 0.001).
The therapeutic effects for a malignant cerebral
glioma were shown at the 10μCi and 50 Cμ i
doses by decreasing the tumor volume and ex-
tending the survival rate. Group 2 appeared to be
superior to group 1 in terms of the level of tumor
destruction according to H-E and TUNEL
staining, but there was no significant difference in
the survival rate and the decreasing rate of the
tumor volume.
Lee et al. have reported that for a skin mela-
noma, a Ho-166 chitosan complex destroyed the
central area of the injection on the tumor as a
result of necrosis, and that the peripheral area,
where the radiation dose was low, showed a halt
in growth.
Immunohistochemical staining indicated that
apoptosis contributed to a halting of the tumor
growth according to the RT-PCR and TUNEL-
staining. However, the morphological findings,
gross analyses and flow cytometry did not reveal
any apoptosis, and morphologically, the cessation
of tumor growth and secondary necrosis appeared
to be caused by necrosis.12
This study also showed consistent findings of
apoptosis according to the TUNEL staining results
and the findings from immunohistochemical
staining. However, according to the morphologi-
cal findings, which showed cavitation, the mecha-
nism of action for the Ho-166 chitosan complex on
the tumor appears to be cytonecrosis. TUNEL
staining indicated that the positive findings were
temporary and reactions to DNA damage were
observed within the area of tumor necrosis.
It is believed that the Ho-166 chitosan complex
has the potential to be an additional tool for the
treatment of a malignant cerebral glioma. How-
ever, research into the appropriate dose is needed
before clinical trials on the human body can com-
mence.
Through our study on the therapeutic effects of
the Ho-166 chitosan complex in the malignant
cerebral tumor model of rats, it was found that the
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Ho-166 chitosan complex can be used for treating
malignant cerebral glioma when injected at the
appropriate dose. The benefits of the Ho-166
chitosan complex are based on minimizing the
irradiation dosage to the normal tissues around
the tumor and intensively irradiating a toxic β
rays dose to the tumor, thereby achieving necrosis
of the malignant tumor without a direct impair-
ment or side effects through dissociation into the
other surrounding organs.
The Ho-166 chitosan complex is dose-depen-
dently effective in the cytonecrosis of a malignant
cerebral glioma, although at an excessive dosage
of 100μCi side effects extending to the surround-
ing normal tissues were observed. It also pro-
longed life substantially by destroying the cere-
bral glioma and halting its growth. However, its
effect on prolonging life was not as great at an
excessive injection dose.
The mechanism of action for destroying the
glioma was coagulation necrosis, as reported in
other studies. In future studies, the Ho-166 chito-
san complex promises to be a supplementary tool
in the treatment of cerebral glioma through an
injection using a stereotactic method, and in the
surgical treatment for recurring tumors through
injection in the surgical field.
Overall, further studies on the appropriate in-
jection dose relative to the tumor volume and the
clinical efficacy will be needed.
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